Rachel Ruckdeschel Smith, Ph.D., joined StrideBio as Vice President of Regulatory Affairs in November 2021. Dr. Smith worked previously for 10 years at Capricor Therapeutics, where as Vice President of Research and Development she helped develop a pipeline of regenerative medicine products. As the first employee and a co-inventor on the key patent licensed to Capricor, her responsibilities spanned a range of functions, including directing internal and external R&D programs, building the company’s grant portfolio, leading the CMC team in a partnered collaboration, and managing the company’s regulatory portfolio. She secured $36 million in grant and loan funding for the company’s manufacturing, preclinical and clinical programs.
She managed a regulatory portfolio inclusive of three products across five clinical indications, leveraging pathways available for the lead orphan pediatric indication. She co-authored dozens of peer-reviewed publications and editorials related to company R&D. She also spent 7 years as a faculty member at the Cedars-Sinai Medical Center Heart Institute and 3 years as an independent consultant. Rachel holds a Ph.D. in biomedical engineering from Johns Hopkins University and a B.S. in biomedical engineering from Tulane University.